Keratomycosis due to Tintelnotia destructans refractory to common therapy treated successfully with systemic and local terbinafine in combination with polyhexamethylene biguanide.


Journal

International ophthalmology
ISSN: 1573-2630
Titre abrégé: Int Ophthalmol
Pays: Netherlands
ID NLM: 7904294

Informations de publication

Date de publication:
Jun 2019
Historique:
received: 06 12 2017
accepted: 16 04 2018
pubmed: 1 5 2018
medline: 8 6 2019
entrez: 30 4 2018
Statut: ppublish

Résumé

To report on a wearer of rigid gas-permeable contact lenses with a keratomycosis due to Tintelnotia-a new genus of Phaeosphaeriaceae-treated with terbinafine and polyhexamethylene biguanide. Chart review of a patient with fungal keratitis treated additionally with systemic and topical terbinafine 0.25% after symptoms increased under conventional antimycotic therapy with voriconazole. Antifungal susceptibility had been tested in vitro. After starting an additional treatment with systemic and topical terbinafine, the severe corneal infection was sufficiently resolved. The drug was well tolerated without any neurological, dermatological or gastroenterological problems. Terbinafine revealed a marked in vitro antifungal activity of 0.12 µg/ml. The fungus was identified as Tintelnotia destructans. Terbinafine might be considered as a therapeutic option in severe cases of fungal keratitis refractory to common antifungal therapy.

Identifiants

pubmed: 29705891
doi: 10.1007/s10792-018-0930-2
pii: 10.1007/s10792-018-0930-2
doi:

Substances chimiques

Antifungal Agents 0
Biguanides 0
Disinfectants 0
polihexanide 322U039GMF
Terbinafine G7RIW8S0XP

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1379-1385

Références

Cornea. 2000 May;19(3):307-12
pubmed: 10832689
Invest Ophthalmol Vis Sci. 2003 Jun;44(6):2634-43
pubmed: 12766067
Ophthalmic Res. 2007;39(2):81-3
pubmed: 17284933
Cornea. 2007 Oct;26(9):1082-6
pubmed: 17893539
Am J Clin Dermatol. 2007;8(6):357-64
pubmed: 18039018
Cornea. 2009 Jul;28(6):638-43
pubmed: 19512908
Chin Med J (Engl). 2009 Aug 20;122(16):1884-8
pubmed: 19781365
Br J Ophthalmol. 2010 Mar;94(3):389-90
pubmed: 20215384
Cornea. 2010 May;29(5):564-8
pubmed: 20335812
Ophthalmology. 2012 Aug;119(8):1516-21
pubmed: 22521083
Ophthalmic Res. 2012;48(4):171-6
pubmed: 22710976
Klin Monbl Augenheilkd. 2015 Jun;232(6):754-64
pubmed: 26084964
Am J Ophthalmol. 2016 Aug;168:227-236
pubmed: 27287820
Ophthalmology. 2016 Nov;123(11):2285-2293
pubmed: 27538797
Mycoses. 2017 Apr;60(4):244-253
pubmed: 27910191
Ophthalmologe. 2018 Nov;115(11):948-950
pubmed: 29273865
Arch Ophthalmol. 1974 Apr;91(4):313-27
pubmed: 4621283

Auteurs

Wolfgang J Behrens-Baumann (WJ)

Department of Ophthalmology, Otto von Guericke University, Magdeburg, Germany.

Wolfram Hofmüller (W)

Department of Ophthalmology, Otto von Guericke University, Magdeburg, Germany.

Ina Tammer (I)

Department of Medical Microbiology, Otto von Guericke University, Magdeburg, Germany.

Kathrin Tintelnot (K)

Mycotic and Parasitic Agents and Mycobacteria, Robert Koch-Institute, Nordufer 20, 13353, Berlin, Germany. tintelnotk@rki.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH